Compare NNNN & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | SANA |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | Germany | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | N/A | 2021 |
| Metric | NNNN | SANA |
|---|---|---|
| Price | $31.82 | $3.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.80 |
| AVG Volume (30 Days) | 14.1K | ★ 3.7M |
| Earning Date | 04-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.58 | $1.99 |
| 52 Week High | $55.65 | $6.55 |
| Indicator | NNNN | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 40.07 |
| Support Level | $26.31 | $3.03 |
| Resistance Level | $44.06 | $3.43 |
| Average True Range (ATR) | 2.86 | 0.20 |
| MACD | 0.59 | -0.03 |
| Stochastic Oscillator | 70.78 | 16.07 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.